Virtual Poster Session in HCC From Chicago - prIME Oncology
Virtual Poster
Virtual Poster

Virtual Poster Session in HCC From Chicago

Practical Application of Key Data Presented During the 2018 Oncology Annual Meeting

Not a member of My prIME? Join now for instant access.

View CME-certified presentations and downloadable slides covering the most up-to-date clinical trial data on hepatocellular carcinoma (HCC) from the 2018 Oncology Annual Meeting in Chicago

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides



1.0 AMA PRA Category 1 Credits

Release Date

Release Date

Jun 12, 2018

Expiration Date

Jun 12, 2019

Masatoshi Kudo, MD, PhD

Abstract #4017: Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

Featured Expert: Masatoshi Kudo, MD, PhD

Markus Peck-Radosavljevic, MD, MBA

Abstract #4018: Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis

Featured Expert: Markus Peck-Radosavljevic, MD, MBA

Ghassan Abou-Alfa, MD, MBA

Abstract #4019: Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial

Featured Expert: Ghassan Abou-Alfa, MD, MBA

Andrew X. Zhu, MD, PhD

Abstract #4020: Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update

Featured Expert: Andrew X. Zhu, MD, PhD

  • Ghassan Abou-Alfa, MD, MBAMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Masatoshi Kudo, MD, PhDKinki University Medical Center
    Osaka, Japan
  • Markus Peck-Radosavljevic, MD, MBAMedical University of Vienna
    Vienna, Austria
  • Andrew X. Zhu, MD, PhDMassachusetts General Hospital
    Boston, Massachusetts, United States

This activity is specifically designed for physicians, nurses and other clinicians who are cancer specialists.

After successful completion of this educational activity, participants should be able to:

  • Discuss key HCC data from the conference
  • Apply key HCC data from the conference to clinical practice, as appropriate


Introduction: The State of Treatment for HER2-Positive Early Breast Cancer in 2018
Featured Expert: Robert Coleman, MD, FRCP, FRCPE

Abstract #506: PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results
Featured Expert: Helena Earl, MBBS, PhD, FACP

Abstract #507: De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study
Featured Expert: Valentina Guarneri, MD, PhD

Abstract #509: HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trial
Featured Expert: Aleix Prat, MD, PhD

Abstract #524: Duration of extended adjuvant therapy with neratinib in early‑stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial
Featured Expert: Michael Gnant, MD, FACS

Abstract #549: Timing of initiation of neratinib after trastuzumab-based adjuvant therapy in early‑stage HER2+ hormone receptor (HR)-negative breast cancer: Exploratory analyses from the phase III ExteNET trial
Featured Expert: Bent Ejlertsen, MD, PhD


Abstract #2000: GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma
Featured Expert: Wolfgang Wick, MD

Abstract #2006: Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients
Featured Expert: David Reardon, MD

Abstract #2047: Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS)
Featured Expert: Giuseppe Lombardi, MD

Neuroendocrine Tumors

Abstract #4094: Additional value of tumour growth rate (TGR) in patients (pts) diagnosed with well-differentiated neuroendocrine tumours (NETs) achieving RECIST-defined stable disease (SD): Subgroup analysis of the GREPONET study
Featured Expert: Angela Lamarca, MD, PhD

Abstract #4095: Assessing prognosis of neuroendocrine neoplasms: Results of a collaborative multinational effort including over 10.000 European patients – The ENETS registry
Featured Expert: Ivan Borbath, MD, PhD

Abstract #4099: First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors
Featured Expert: Jonathan Strosberg, MD


Abstract #11504: Results of randomized, placebo (PL)-controlled phase II study evaluating efficacy and safety of regorafenib (REG) in patients (pts) with metastatic osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and Unicancer
Featured Expert: Florence Duffaud, MD

Abstract #11508: Results of a prospective randomized phase III T-SAR trial comparing trabectedin (T) vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS): A French Sarcoma Group (FSG) trial
Featured Expert: Axel Le Cesne, MD

Abstract #11505: A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study
Featured Expert: Richard Riedel, MD

This educational activity is supported by a grant from Bayer HealthCare Pharmaceuticals, Inc.; Ipsen; and Puma Biotechnology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Virtual Poster Session in HCC From Chicago - prIME Oncology

prIME Oncology designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the post-test are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Abou-Alfa has disclosed that he has received consulting fees from Agios Pharmaceuticals; Amgen; Aptus Pharmaceuticals, Inc.; ASLAN Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Bayer; Bristol-Myers Squibb; Boston Scientific Corporation; CARsgen Therapeutics; CASI Pharmaceuticals, Inc.; Celgene Corporation; CytomX Therapeutics; Daiichi Sankyo; Debiopharm Group; Delcath Systems Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Halozyme, Inc.; Inovio Pharmaceuticals, Inc.; Ipsen; Merck & Co., Inc.; MedImmune; Onxeo; PCI Biotech; Sanofi-Aventis; Servier; Silenseed; SillaJen Inc; Sirtex; and Yakult Pharmaceutical Industry. He has received grant/research support from Agios Pharmaceuticals; Array BioPharma; AstraZeneca; Bayer; Bristol-Myers Squibb; CASI Pharmaceuticals, Inc.; Celgene Corporation; Exelixis; F. Hoffmann-La Roche Ltd.; Genentech, Inc.; Incyte Corporation; Lilly; MabVax Therapeutics Holdings, Inc.; MedImmune; Momenta Pharmaceuticals; and OncoMed Pharmaceuticals (research support to institution). He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kudo has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Peck-Radosavljevic has disclosed his role of investigator for AbbVie, Arqle-Daiichi, Bayer, Bristol-Myers Squibb, Boehringer­lngelheim, ImClone, Lilly, MSD, Novartis Oncology, and Roche. He has been a speaker and advisor for AbbVie, Bayer, Bristol-Myers Squib, Boehringer-lngelheim, Eisai, Ipsen, Lilly, MSD, and Roche. He has received grant support from AbbVie, Arqle-Daiichi, Bayer, MSD, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Zhu has disclosed that he has received consulting fees from Bayer HealthCare Pharmaceuticals, Inc., Bristol-Myers Squibb, Merck, and Novartis Oncology. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Amy Furedy, RN, OCN (clinical content reviewer/planner) – no relevant financial relationships
  • Angela Zimmerman, PhD (clinical content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.